Endometriosis, a condition affecting an estimated 190 million people worldwide, could soon be diagnosed far more quickly thanks to a blood test developed by researchers at the University of Edinburgh. The test identifies a unique pattern of hormones—particularly androgens—that appears only in individuals with the disease, with an accuracy exceeding 95%.
Currently, diagnosis relies on pelvic exams, ultrasound, MRI, or laparoscopic surgery, a minimally invasive procedure that requires incisions. This process often takes up to 12 years, according to the World Health Organization, delaying treatment and allowing the condition to progress. In the United Kingdom, the average wait is over nine years, said Emma Cox, chief executive of Endometriosis UK. “For too long, those with endometriosis have faced unacceptably long waits for diagnosis,” she added.
Hormonal Fingerprint
The study, published by a team led by Douglas Gibson, focused on androgens—sex hormones such as testosterone that are vital for reproductive health, bone density, and muscle mass. While oestrogens have long been linked to endometriosis, the role of androgens was less understood. The researchers analysed blood samples from 159 women with confirmed endometriosis and 57 without the condition, measuring levels of various androgens, including a group called 11-oxygenated androgens produced by the adrenal glands.
They found that women with endometriosis had significantly higher levels of 11-ketotestosterone, an androgen that helps build muscle and supports the growth of sex organs. This distinct hormonal fingerprint allowed the team to distinguish between patients and controls with remarkable precision. “These findings mark a significant breakthrough in our understanding of endometriosis,” said Gibson, co-author of the study.
The implications are substantial. A simple blood test could replace invasive procedures and reduce diagnostic delays, particularly in low- and middle-income countries where access to laparoscopy and imaging is limited. Early diagnosis is critical: untreated endometriosis can lead to chronic pain, infertility, and reduced quality of life.
While the results are promising, the study is relatively small, and larger trials will be needed to confirm the test’s reliability across diverse populations. The researchers are now planning to validate their findings in broader cohorts, including women from different European countries and ethnic backgrounds.
This development comes amid growing attention to women’s health in Europe. The European Parliament has called for better funding and awareness of endometriosis, and several member states, including France and Italy, have launched national strategies to improve diagnosis and care. The Edinburgh study adds a powerful tool to that effort.
For patients like those in the UK, where the average diagnosis takes nearly a decade, the test could be transformative. “It’s a game-changer,” said Cox, urging health systems to prepare for its adoption. The research also highlights the importance of funding basic science: understanding the hormonal underpinnings of endometriosis may open new avenues for treatment.
As Europe grapples with rising healthcare costs and an ageing population, innovations that reduce invasive procedures and speed up diagnosis are especially valuable. The blood test, if validated, could be rolled out across the continent, from clinics in Berlin to hospitals in Barcelona, offering millions of women a faster path to relief.
